Compare BMRC & CUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMRC | CUVL |
|---|---|---|
| Founded | 1989 | N/A |
| Country | United States | Australia |
| Employees | N/A | 16 |
| Industry | Major Banks | Miscellaneous |
| Sector | Finance | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.4M | 374.2M |
| IPO Year | 2007 | N/A |
| Metric | BMRC | CUVL |
|---|---|---|
| Price | $27.72 | $5.96 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $28.67 | N/A |
| AVG Volume (30 Days) | ★ 126.8K | 20.4K |
| Earning Date | 04-27-2026 | N/A |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.11 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $391.81 | N/A |
| Revenue Next Year | $6.13 | N/A |
| P/E Ratio | $24.68 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.50 | $5.90 |
| 52 Week High | $30.92 | $8.20 |
| Indicator | BMRC | CUVL |
|---|---|---|
| Relative Strength Index (RSI) | 51.11 | 37.37 |
| Support Level | $25.42 | N/A |
| Resistance Level | $28.32 | $6.89 |
| Average True Range (ATR) | 0.74 | 0.45 |
| MACD | 0.11 | -0.10 |
| Stochastic Oscillator | 84.39 | 3.33 |
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties, and others. The majority of its revenue comes from interest income.
Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the US.